Staff

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022

-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as...

Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Deals position Optimi Life nutraceutical brand for international distribution Optimi Life Optimi Life Bundle Optimi Life Optimi Life Optimi Life...

Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and Dermatology Conference

Sofwave to host showcase booth from September 1-4Facial and neck treatment workshop held on September 2SUPERB neck, skin, and eyebrow...

Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker

Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunctionMIAMI, Aug....

error: Content is protected !!